The importance of presurgical somatostatin analogue therapy in acromegaly

Endokrynologia Polska

Volumn 58, Issue 4, 2007, Pages 356-360

  Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Acromegaly; Pituitary tumour surgery; Somatostatin analogues; Tumour shrinkage

Indexed keywords

DRUG DERIVATIVE; HORMONE; SOMATOSTATIN;

ACROMEGALY; HUMAN; MULTIMODALITY CANCER THERAPY; REVIEW; TREATMENT OUTCOME;

ACROMEGALY; COMBINED MODALITY THERAPY; HORMONES; HUMANS; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 38449107688     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Holdaway IM, Rajasoorya CR. Epidemiology of acromegaly. Pituitary 1999; 2: 29-41.
2. Colao A, Ferone D, Marzullo P et al. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 2004; 25: 102-152.
3. Melmed S, Casanueva FF, Cavagnini F et al. Guidelines for Acromegaly Management. J Clin Endocrinol Metab 2002; 87: 4054-4058.
4. Colao A, Pivonello R, Auriemma RS et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogues in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006; 91: 2112-2118.
5. Ben-Shlomo A, Melmed S. The role of pharmacotherapy in perioperative management of patients with acromegaly. J Clin Endocrinol Metab 2003; 88: 963-968.
6. Kopchick JJ, Parkinson C, Stevens EC et al. Growth hormone receptor antagonist: discovery, development and use in patients with acromegaly. Endocr Rev 2002; 23: 623-646.
7. Colao A, Pivonello R, Auriemma RS et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 2006; 154: 467-477.
8. Muravchick S. Preoperative assessment of the elderly patient. Anesthesiol Clin North America. 2000; 18: 71-89.
9. Lissett CA, Peacey SR, Laing I et al.The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol (Oxf) 1998; 49: 653-657.
10. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical "cure". Eur J Endocrinol 2005; 152: 379-387.
11. Barker FG 2nd, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003; 88: 4709-4719.
12. Cappabianca P, Cavallo LM, Colao A et al. Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas. J Neurosurg 2002; 97: 293-298.
13. Seidman PA, Kofke WA, Policare R et al. Anesthetic complications in acromegaly. Br J Anaesth. 2000; 84: 179-182.
14. Giustina A, Boni E, Romanelli G et al. Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol. 1995; 75: 1042-1047.
15. Colao A, Ferone D, Cappabianca P et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997; 82: 3308-3314.
16. Lombardi G, Colao A, Marzullo P et al Multicenter Italian Study Group on Lanreotide. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest 2002; 11: 971-976.
17. Vitale G, Pivonello R, Auriemma RS et al.Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf) 2005; 63: 470-476.
18. Ip MS, Tan KC, Peh WC et al. Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol (Oxf) 2001; 55: 477-483.
19. Herrmann BL, Wessendorf TE, Ajaj W et al. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol 2004; 151: 309-315.
20. Koop BL, Harris AG, Ezzat S. Effects of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol 1994; 130: 581-586.
21. Hoogwerf BJ. Postoperative management of the diabetic patient. Med Clin North Am 2001; 85: 1213-1228.
22. Barkan AL, Burman P, Clemmons DR et al. Glucose homeostasis and safety in patients with acromegaly converted from longacting octreotide to pegvisomant. J Clin Endocrinol Metab 2005; 90: 5684-5691.
23. Lindberg-Larsen R, Moller N, Schmitz O et al. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 2007; 92: 1724-1728.
24. Colao A, Martino E, Cappabianca P et al.; A.L.I.C.E. Study Group. First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest 2006; 29: 1017-1020.
25. Biermasz NR, van Dulken H, Roelfsema F. Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 1999; 84: 3551-3555.
26. Plockinger U, Quabbe HJ. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta Neurochir (Wien). 2005; 147: 485-493.
27. Losa M, Mortini P, Urbaz L et al. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neurosurg 2006; 104: 899-906.
28. Barkan A, Lloyd RV, Chandler WF et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988; 67: 1040-1048.
29. Plöckinger U, Reichel M, Fett U et al. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab. 1994; 79: 1416-1423.
30. Lucas-Morante T, García-Uría J, Estrada J et al. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J Neurosurg 1994; 81: 10-14.
31. Stevenaert A, Beckers A. Presurgical octreotide: treatment in acromegaly. Metabolism 1996; 45 (supl 1): 72-74.
32. Newman CE, Melmed S, George A et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3034-3040.
33. Tamura M, Yokoyama N, Abe Y et al. Preoperative treatment of growth hormone-producing pituitary adenoma with continuous subcutaneous infusion of octreotide. Endocr J 1998; 45: 269-275.
34. Tachibana E, Saito K, Yoshida J. Preoperative short-term administration of octreotide for facilitating transsphenoidal removal of invasive growth hormone-secreting macroadenomas. Neurol Med Chir (Tokyo). 1999; 39: 496-499.
35. Kristof RA, Stoffel-Wagner B, Klingmüller D et al. Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study. Acta Neurochir (Wien) 1999; 141: 399-405.
36. Baldelli R, Colao A, Razzore P et al. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 2000; 85: 4099-4103.
37. Colao A, Ferone D, Marzullo P, Cappabianca P et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001; 86: 2779-2786.
38. Abe T, Lüdecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical center. Eur J Endocrinol 2001; 145: 137-145.
39. Amato G, Mazziotti G, Rotondi M et al. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 2002; 56: 65-71.
40. Bevan JS, Atkin SL, Atkinson AB et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002; 87: 4554-4563.
41. Colao A, Pivonello R, Rosato F et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 2006; 64: 342-351.